Showing posts with label doctor. Show all posts
Showing posts with label doctor. Show all posts

Monday, 28 July 2008

Your DNA's in the post

Fancy being told you have a higher-than-average chance of getting prostate cancer but are at low risk of glaucoma? Now for about £500 you can have your genetic make-up analysed. Rob Liddle swabbed his cheek and sent off for a scan.
An e-mail pops into my basket to say the results of my genetic scan are ready. I have a few minutes free - shall I take a peep now or wait until I can devote the time to digest the results properly?
Curiosity gets the better of me and I log on to the Decodeme website to view my password-protected "gene profile".
This is quite exciting - could what I find out in the next few minutes alter the course of my life? I'm curious by nature, but that doesn't extend to wanting to know when the Grim Reaper is going to come a-knocking.
Up pops a list of grisly conditions - most of which are familiar to me, indeed some of them lurk in my family history.
And it's the ones that have touched my life that I am drawn to first. I click on Heart Attack, bypass the warm-up "introduction" to the condition, and head straight for my own "risk summary".
I'm told: "According to the selected literature, the relative genetic risk calculated from your genotype for males of European ancestry is 0.90.
"This corresponds to a 44.2% lifetime risk of developing heart attack, which is 10% less than for males of European ancestry in general."
Fated to be fat?
So far so good, I suppose, but that's still a high risk and I'm not celebrating with a full English breakfast yet.
I scan the list of 25 traits again and settle on Crohn's disease. Here I'm told the research indicates that I have a lifetime risk 1.42 times the average. Not so good. But for Diabetes, types 1 and 2, better news.
Next I plump for Obesity - surely a banker. These genes make me look fat, right? No, a lower-than-average risk. I can't use that as an excuse for my fuller figure.
A number of personal genomics firms, including Iceland-based Decodeme and 23andme and Navigenics, in the US, are now directly selling tests to the public that assess genetic risks of suffering from certain conditions.
Some also provide information about your ancestral origins.
After receiving a sample taken from the inside of your cheek, Decodeme analyses up to one million DNA markers, annotates them and puts them in the context of disease risk, providing you with a personal profile.
'Do more exercise'
One reason the tests have proved controversial is that they can measure only the genes that studies have linked to certain conditions - not the many that have yet to be discovered.
Decodeme says it is continually adding the results of new research to its database, improving the accuracy of the existing risk summaries and extending the list of traits for which you can assess yourself.
But there are other risk factors that could easily override these genetic indications, such as family history and lifestyle. My genetic risk of getting type 2 diabetes is rated as below average, but being overweight probably counts for more.
Steve Jones, author and professor of genetics at University College, London, believes that, in most cases, individual genes cannot say much about a person's risk. For him, potential customers would be better off following the advice of the health lobby.
"It is a new form of diagnosis - before any symptoms manifest themselves - but really what everybody should do is smoke less, eat less and do more exercise," he says.
The Decodeme website has a section on risk factors and prevention for each of the conditions featured, which I later peruse.
From this I learn that the prevalence for Crohn's is highest during the second and third decades of life - but that it can crop up in the over-70s. I'm 42, so may have dodged that bullet.
And if I still have questions, I can message Decodeme's team, who may then refer me to a genetic counsellor.
But for some critics, discovering your risk of developing a serious condition from a web page rather than a doctor presents a serious problem - even if the scans are unlikely to throw up any catastrophic results.
The authorities in some states in the US have recently warned testing companies that they should not continue to solicit business from residents unless the process is being sanctioned by a licensed physician.
'Reduced autonomy'
Daniel Sokol, a lecturer in medical ethics at the University of London, says the absence of the direct doctor-patient relationship does create a problem.
"The results could allow people to make changes for the better to their lifestyle," says Dr Sokol.
"However, if they misinterpret them - the scans could do more harm than good and could actually reduce people's autonomy if they interpret the results incorrectly or exaggerate their implications."
But Kari Stefansson, chief executive of Decodeme, says it should be a matter of personal choice how people treat their own data.
"The people who feel that they want to go over the results with a doctor should go to a doctor," he says.
"When I got mine, I went into the office and closed the door. I wanted to be alone.
"It should be your decision - we are not ramming it down anyone's throat. How you use it depends on who you are, but you are entitled to make the choice of getting the information or not getting it.
"But you can get so much out of it - it could be extremely beneficial to know that you are at a higher risk."
Dr Stefansson admits that the cost of the test at $985 probably puts it out of reach for most people, but he predicts a future in which accessing such personal genetic information will be commonplace - with the tests possibly costing a 10th of what they do now in five years' time.
We go through my results together. I appear to have a slightly increased chance of suffering macular degeneration (an eye problem), coeliac disease and Crohn's, but there is nothing in my risk summary that indicates that I need to take further medical advice immediately.
"I'm afraid to tell you that you are just an average guy," jokes Dr Stefansson.
Perhaps this news is the hardest of all to take.

Saturday, 26 July 2008

Prominent Cancer Doctor Warns About Cellphones

The head of a prominent cancer research institute has warned his faculty and staff to limit cellphone use because of a possible cancer risk, The Associated Press reports.
Dr. Ronald B. Herberman, the director of the University of Pittsburgh Cancer Institute, notes that while the evidence about a cellphone-cancer link remains unclear, people should take precautions, particularly for children.
“Really at the heart of my concern is that we shouldn’t wait for a definitive study to come out, but err on the side of being safe rather than sorry later,” Dr. Herberman told The Associated Press.
Earlier this year, three prominent brain surgeons raised similar concerns while speaking on “The Larry King Show.” Their concerns were largely based on observational studies that showed only an association between cellphone use and cancer, not a causal relationship. The most important of these studies is called Interphone, a vast research effort in 13 countries, including Canada, Israel and several in Europe.
Some of the research suggests a link between cellphone use and three types of tumors: glioma; cancer of the parotid, a salivary gland near the ear; and acoustic neuroma, a tumor that essentially occurs where the ear meets the brain. All these tumors are rare, so even if cellphone use does increase risk, the risk is still very low.
On Wednesday, Dr. Herberman sent a memo to about 3,000 faculty and staff saying that children should use cellphones only for emergencies because their brains are still developing. He advised adults to keep cellphones away from the head and use the speakerphone or a wireless headset, he said.
“Although the evidence is still controversial, I am convinced that there are sufficient data to warrant issuing an advisory to share some precautionary advice on cellphone use,” he wrote in his memo.

Wednesday, 23 July 2008

Brain-damaged dieter gets payout

A woman has been awarded more than £800,000 after suffering brain damage on a detox diet.
Dawn Page, 52, claimed she was told to drink more water and reduce her salt intake during The Amazing Hydration Diet.
The High Court was told she suffered uncontrollable vomiting after starting the diet, but nutritionist Barbara Nash assured her it was part of the detoxification process.
Mrs Nash's insurance company agreed to pay out £810,000 although she denied any wrongdoing.
In October 2001 Mrs Page was less than a week into the regime when she suffered an epileptic fit and was taken to Princess Margaret Hospital in Swindon.
Doctors were unable to prevent her suffering permanent brain damage and her memory, speech and concentration have been affected.
Her husband Geoff Page, 54, of Farringdon, Wiltshire, said: "Just days after she started the Hydration Diet, she began to feel unwell and started vomiting. Things went from bad to worse, and within another couple of days she collapsed with the fit."
Plexus Law, representing Mrs Nash all allegations of substandard practice levelled at Mrs Nash "have always been and continue to remain firmly denied".
The firm added: "Equally the information contained in the medical records suggesting that Mrs Page appeared to have drunk five litres of water on the day that she was admitted to hospital, and therefore disregarded advice given by our client, were also denied by Mrs Page.
"In our view as a recognition of this, the settlement amount agreed to be paid was less than half the total amount claimed and the compromise which was offered and accepted was on the basis of no admission of liability."

Wednesday, 16 July 2008

Avastin - Wet Macular Degeneration: by Donald Arson

Avastin is the brand name for Bevaciumab a monoclonal antibody or an antibody that is an identical clone of a single parent cell. It was approved in 2004 by the FDA for use in the treatment of some cancers and is used as a first or second line treatment for patients.
As the first clinically available angiogenesis inhibitor the United States it inhibits new cancer cells by blocking the growth of blood vessels in pre-existing tumors. A solid, non-liquid, tumor needs to grow additional blood vessels to be able to reach a certain size.
With an angiostatic agent such as Avastin the growth of new blood vessels is slowed stopping the cancer from growing indefinitely. It is usually given every 14 days intravenously in the arm and can be used with other drugs in combination and with intravenous 5-fluorouracilâ€"based chemotherapy.
Developed by Genentech (NYSE: DNA), a leading biotechnology corporation, it is marketed in the United States under the Genentech name and outside the US under Roche.
When it was originally available in 2004 it was only FDA approved for the treatment of many forms of small cell lung cancer and metastatic colon cancer. A metastatic cancer, in this case colon cancer, is a cancer that spreads from one part or organ to another non-adjacent part or organ.
In 2008 the FDA opened up the doors and allowed for the treatment of breast cancer. There are also clinical trials under way to use Avastin for the treatment of non-metastatic colon cancer, metastatic renal cell carcinoma, metastatic breast cancer, metastatic glioblastoma multiform, metastatic hormone-refractory prostate cancer, metastatic or unresectable locally advanced pancreatic cancer, and metastatic ovarian cancer.
Avastin is also currently being used off-label, the practice of prescribing drugs for a purpose outside the scope of the drug's approved label, for the treatment of wet macular degeneration by some retinal specialists.
Wet macular degeneration or AMD is a condition that causes loss of vision from the growth of abnormal blood vessel choriocapillaries, through Bruch's membrane. This eventually leads to blood and protein leaking below the macula, an oval spot near the middle of the retina in the human eye. With AMD rapid, often irreversible vision loss can occur through the leaking, bleeding and scaring of the blood vessels if left untreated.
Dr. Philip J Rosenfeld, MD, PhD of the Bascom Palmer Eye Institute conducted a study that showed positive results for the treatment of AMD with Avastin. According to Dr. Rosenfeld’s study Avastin improved vision in as little as one week for patients treated for AMD.
For AMD treatment Avastin is used in very low amounts by retinal specialists. They usually have a pharmacists transfer the drug from the original vile to a pre-filled needles containing single doses. The specialists will then usually treat the patient in their own office.
As with any drug it is always best to talk to your doctor or pharmacist before starting any treatment

Tuesday, 15 July 2008

Medical Problem

An old woman came into her doctor's office and confessed to an embarrassing problem. "I do that all the time, Doctor Johnson, but they're soundless, and they have no odor. In fact, since I've been here, I did it no less than twenty times. What can I do?"
"Here's a prescription, Mrs. Harris. Take these pills three times a day for seven days and come back and see me in a week."
Next week an upset Mrs. Harris marched into Dr. Johnson's office. "Doctor, I don't know what was in those pills, but the problem is worse! I'm doing it just as much, but now it smells terrible! What do you have to say for yourself?"
"Calm down, Mrs. Harris," said the doctor soothingly. "Now that we've fixed your sinuses, we'll work on your hearing!!!"